Business Context and Reporting Period
Company: Summit Therapeutics plc (Summit Therapeutics Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended January 31, 2017
Business Overview: Summit is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection (CDI). The company has no approved products and has incurred losses since inception. It relies on equity issuances, collaboration agreements (notably with Sarepta Therapeutics), and grants to fund operations.
Key Financial Metrics
| Metric | 2017 (USD) | 2017 (GBP) | 2016 (GBP) |
|---|---|---|---|
| Revenue | $2,899 | £2,304 | £0 |
| Other Operating Income | $90 | £72 | £1,281 |
| Operating Loss | $(31,279) | (£24,853) | (£20,346) |
| Net Loss | $(26,897) | (£21,371) | (£20,137) |
| Cash and Cash Equivalents | $35,316 | £28,062 | £16,304 |
| Working Capital | $(7,076) | (£5,621) | £1,327 |
| Total Assets | $47,304 | £37,587 | £25,057 |
| Total Equity (Deficit) | $(4,396) | (£3,493) | £16,080 |
Note: USD figures are translated at the rate of £1.00 = $1.2585. Financial data for 2016 has been adjusted retrospectively due to a change in accounting policy regarding charitable funding arrangements.
Material Changes vs. Prior Period
- Revenue Recognition: The company recorded revenue of $2.9 million in 2017, compared to zero in 2016. This stems from the recognition of a portion of the $40 million upfront payment received from Sarepta Therapeutics in October 2016, which is being recognized over the development period.
- Net Loss Increase: Net loss increased to £21.4 million in 2017 from £20.1 million in 2016 (adjusted). This was driven by increased research and development (R&D) expenses, particularly for the DMD and CDI programs.
- Working Capital Deterioration: Working capital shifted from a positive £1.3 million in 2016 to a negative £5.6 million in 2017, reflecting increased current liabilities relative to current assets.
- Accounting Policy Change: A change in accounting policy regarding charitable funding (Wellcome Trust, MDA, DPF) reclassified certain funding from grant income to financial liabilities, resulting in the recognition of finance costs and a reduction in historical other operating income.
Guidance, Outlook, and Risks
Outlook and Capital Resources
Management believes existing cash and cash equivalents, combined with an anticipated $22.0 million milestone payment from Sarepta (payable on or after April 1, 2017), will fund operations through December 31, 2018. However, the company explicitly states it does not expect these resources to be sufficient to complete its planned randomized, placebo-controlled clinical trial for ezutromid (DMD) or the two planned Phase 3 trials for ridinilazole (CDI) without significant additional capital.
Key Milestones and Programs
- Ezutromid (DMD): The Phase 2 "PhaseOut DMD" trial is ongoing. The company expects to report 24-week biopsy, MRI, and functional data in the first quarter of 2018. A $22 million milestone from Sarepta is contingent on the first dosing of the last patient in this trial.
- Ridinilazole (CDI): The company plans to commence two Phase 3 clinical trials in the first half of 2018. It is currently exploring funding options, including third-party collaborations or non-dilutive government/charitable funding.
Material Risks
- Need for Additional Financing: The company has an accumulated deficit of £73.8 million and expects to incur increasing losses. Failure to raise capital could force delays or elimination of development programs.
- Clinical Trial Uncertainty: Success depends on the safety and efficacy of ezutromid and ridinilazole. Previous trials showed variable plasma levels for ezutromid, and the company faces risks regarding patient enrollment and regulatory approval.
- Dependence on Sarepta: Summit relies on Sarepta for commercialization in Europe and other territories. Termination of this agreement could materially harm the business.
- Brexit: As a UK-incorporated company, the withdrawal from the EU creates uncertainty regarding regulatory pathways, currency exchange rates, and market access.
Investor Verification Checklist
- Cash Runway: Verify the timing and certainty of the $22 million Sarepta milestone payment, as the company's liquidity through 2018 depends on it.
- PhaseOut DMD Data: Monitor the Q1 2018 data release for the Phase 2 ezutromid trial, specifically regarding utrophin expression and functional endpoints, to assess the viability of the lead DMD candidate.
- Ridinilazole Funding: Confirm if the company secures a partner or non-dilutive funding for the Phase 3 CDI trials before the current cash reserves are depleted.
- Accounting Adjustments: Review the impact of the financial liability reclassification on future finance costs and the recognition of grant income.
- Intellectual Property: Assess the strength of the patent portfolio, particularly for ridinilazole, which lacks composition-of-matter protection for the active pharmaceutical ingredient alone.